Therapeutic plasmapheresis for post-operative hepatic failure.
It goes without saying that post-surgical hepatic failure must be treated. But today, the prognosis is very poor. The reasons for this are that HF is usually accompanied by hemostatic disorders and PHF, and the patients have fresh wounds and are under surgical stress. Moreover, there is no treatment, except PE, and this requires an anticoagulant. Nafamostat Mesilate (FUT-175) was invented as a serine protease inhibitor. It is short acting, and its degradation does not require the liver. FUT-175 was applied as an anticoagulant to 15 PHF patients with bleeding. There were no side effects and no aggravation of bleeding. Based on these results, FUT-175 is thought to be an ideal anticoagulant.
Tani
T
T
First Department of Surgery, Shiga University of Medical Science, Japan.
Endo
Y
Y
Yoshioka
T
T
Aoki
H
H
Matsuda
K
K
Numa
K
K
Hanasawa
K
K
Kodama
M
M
D000925:Anticoagulants / Q000627:therapeutic use; D001550:Benzamidines; D006146:Guanidines / Q000627:therapeutic use; D006801:Humans; D008107:Liver Diseases / Q000150:complications / Q000628:therapy*; D010951:Plasma Exchange; D010956:Plasmapheresis; D011183:Postoperative Complications / Q000628:therapy*; D011379:Prognosis
D000925:Anticoagulants; D001550:Benzamidines; D006146:Guanidines; C032855:nafamostat